Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RC2DK133947 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
| Mayo Clinic | OTHER |
| California Institute of Technology | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
Celiac disease is an autoimmune enteropathy characterized by chronic inflammation of the small intestinal mucosa triggered by gluten uptake that occurs in genetically susceptible individuals carrying the specific class II human leucocyte antigens (HLA) DQ2 and DQ8 alleles. There is a spectrum in intestinal tissue damage associated with celiac disease. Some individuals develop inflammatory immunity in the absence of tissue damage, while others experience tissue damage ranging from partial to total villous atrophy. Persistent mucosal damage is associated with several severe complications, including lymphoproliferative malignancy and bone diseases. In addition, individuals with active celiac disease display a wide range of clinical symptoms, including metabolic defects that are not correlated to the degree of villous atrophy. Although much progress has been made in understanding celiac disease, major gaps remain in understanding biological mechanisms underlying inter-individual differences in clinical presentations and capacity to heal while maintaining a gluten-free diet.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Gluten challenge group | Experimental | Diagnosis of celiac disease by intestinal biopsy and serology for at least 12 months |
|
| Gluten de-challenge group | No Intervention | Suspected celiac disease either showing typical symptoms or positive celiac disease serology | |
| Control group | No Intervention | No history or symptoms of celiac disease |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gluten containing snack bar | Dietary Supplement | Ingest snack bars containing 3 grams of gluten every day for 6 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Gluten challenge group: quantitative analysis of intestinal villus to crypt ratios | villus to crypt ratios will be quantified on small bowel biopsy samples for the histologic quantification of intestinal responses to disease processes. | baseline - 6 weeks |
| Gluten de-challenge group: quantitative analysis of intestinal villus to crypt ratios | Villus to crypt ratios will be quantified on small bowel biopsy samples for the histologic quantification of intestinal responses to disease processes. | baseline -12 months |
Not provided
Not provided
Inclusion Criteria:
Gluten challenge group:
Gluten de-challenge group:
Control group:
Exclusion Criteria:
Gluten challenge group:
Gluten de-challenge group:
Control group:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sonia Kupfer, MD | Contact | (773) 834-1438 | skupfer@bsd.uchicago.edu | |
| Kristi Kearney, RN | Contact | 773-834-7414 | kkearney@bsd.uchicago.edu |
| Name | Affiliation | Role |
|---|---|---|
| Bana Jabri, MD | University of Chicago | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| California Institute of Technology | Not yet recruiting | Pasadena | California | 91125 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 16, 2025 | May 7, 2026 | Prot_SAP_002.pdf |
| ICF | No | No | Yes | Informed Consent Form | Feb 26, 2026 | May 7, 2026 | ICF_003.pdf |
Not provided
| ID | Term |
|---|---|
| D002446 | Celiac Disease |
| ID | Term |
|---|---|
| D008286 | Malabsorption Syndromes |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| The University of Chicago | Recruiting | Chicago | Illinois | 60637 | United States |
|
| Mayo Clinic | Recruiting | Rochester | Minnesota | 55902 | United States |
|
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |